Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 5
1983 2
1984 2
1985 3
1986 7
1987 1
1988 2
1989 2
1991 2
1992 6
1993 6
1994 9
1995 13
1996 21
1997 20
1998 17
1999 20
2000 30
2001 26
2002 36
2003 51
2004 51
2005 60
2006 63
2007 77
2008 103
2009 105
2010 123
2011 125
2012 174
2013 221
2014 223
2015 257
2016 263
2017 285
2018 318
2019 403
2020 532
2021 615
2022 709
2023 704
2024 838
2025 1050
2026 525

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,249 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hong h[Author] (6,277 results)?
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
Xiong A, Yao W, Zheng W, Yu Y, Chen P, Zhong H, Ge J, Wang H, Chen B, Wang H, Fan Y, Yang Y, Pu X, Song X, Wang Q, Du X, Huang Z, Li X, Luo H, Yao Y, Yu Q, Su C, He L, Jiang G, Cui J, Liu C, Yi T, Che G, Liu Z, Zhang L, Zhou M, Fang Y, Wei Y, Qing Y, Jin X, Zhou C. Xiong A, et al. Among authors: zhong h. Lancet. 2026 May 29:S0140-6736(26)00968-2. doi: 10.1016/S0140-6736(26)00968-2. Online ahead of print. Lancet. 2026. PMID: 42214392
Tissue-resident microbiota impacts colorectal cancer progression and prognosis.
Shi Z, Ren H, Lin C, Li F, Wu M, Yang F, Luo T, Nunes L, Isaksson A, Hammarström K, Zhu T, Zhu S, Zhong Y, Ljuslinder I, Uhlén M, Palmqvist R, Glimelius B, Wu K, Sjöblom T, Zhong H. Shi Z, et al. Among authors: zhong h. Nat Commun. 2025 Dec 7;17(1):346. doi: 10.1038/s41467-025-67047-2. Nat Commun. 2025. PMID: 41354681 Free PMC article.
IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses.
Fei Y, Liu L, Ma S, Jin Y, Wang S, Zhang L, Yang J, Liu Y, Lu M, Xue J, Li J, Chen X, Wang J, Yao Y, Liu C, Zhang J, Han X, Fu J, Kang Z, Wang Y, Sun X, Zhang C, He T, Liu Z, Guo L, Chen C, Zhao H, Gao X, Zhong H, Wen L, Yu X, Liu Z, Zhou Q. Fei Y, et al. Among authors: zhong h. Nat Commun. 2026 May 21. doi: 10.1038/s41467-026-73383-8. Online ahead of print. Nat Commun. 2026. PMID: 42168171 Free article.
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B; CAMPASS Investigators. Zhong H, et al. Lancet Oncol. 2026 Apr;27(4):419-431. doi: 10.1016/S1470-2045(26)00049-5. Epub 2026 Mar 10. Lancet Oncol. 2026. PMID: 41825453 Clinical Trial.
7,249 results